Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model

CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation

(2015) Hamid Zia et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation

(2014) J J M A Hendrikx et al.   BRITISH JOURNAL OF CANCER

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

(2013) Philippa Cheetham et al.   CANCER JOURNAL

Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry

(2013) J. J. M. A. Hendrikx et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors

(2012) S. Rottenberg et al.   CANCER RESEARCH

P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

(2012) Jeroen J.M.A. Hendrikx et al.   INTERNATIONAL JOURNAL OF CANCER

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

(2011) Maurizio Belfiglio et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry

(2011) Jeroen J.M.A. Hendrikx et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice

(2010) F. Li et al.   DRUG METABOLISM AND DISPOSITION

Profiling the expression of cytochrome P450 in breast cancer

(2010) Graeme I Murray et al.   HISTOPATHOLOGY

Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas

(2010) Manmeet S. Ahluwalia et al.   JOURNAL OF NEURO-ONCOLOGY

Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens

(2010) F. Grossi et al.   ONCOLOGIST

Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity

(2009) R. A.B. van Waterschoot et al.   CANCER RESEARCH

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

(2009) Davide Mauri et al.   CANCER TREATMENT REVIEWS

Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

(2009) R. L. Oostendorp et al.   CLINICAL CANCER RESEARCH

Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel

(2009) S L W Koolen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Docetaxel: its role in current and future treatments for advanced gastric cancer

(2009) Masahiko Nishiyama et al.   Gastric Cancer

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

(2008) S. Harmsen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY